Clinical trials: HCC - Hepatocellular Carcinoma, open to volunteers
Hepatocellular Carcinoma (HCC)
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07291076
- Testing
- Pumitamig, Ipilimumab
- Where
- 67 sites in United States, Australia and 12 more
- Volunteers
- 198 people
- Sponsor
- Bristol-Myers Squibb
Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies.
- Conditions
- Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
- Trial name
- NCT07419841
- Testing
- CTX-10726
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Compass Therapeutics
Liver Cancer, Hepatocellular Carcinoma (HCC)
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
This is a research study to evaluate change in Quality of Life, as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC C-30), from baseline to 1 month post…
- Trial name
- NCT04933435
- Testing
- Quality of life questionnaires
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Duke University
Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma
Breath Research Narrow Validation for Gastrointestinal Cancer Detection
The investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlier, including cancers of the oesophagus (food pipe), stomach, pancreas, liver and bowel.
- Conditions
- Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- BRAVE (NCT07714538)
- Where
- 6 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Imperial College London
Hepatocellular Carcinoma (HCC)
68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
This is a prospective, single-center, single-arm, phase I/II study designed to evaluate (1) the safety, tolerability, and imaging characteristics of 68Ga-NYM207 (Phase A), and (2) the diagnostic performance of 68Ga-NYM207 in…
- Trial name
- NYHCC (NCT07590336)
- Testing
- 68Ga-NYM207 PET/CT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
The goal of this clinical trial is to learn if adding PULSAR, a personalized adaptive stereotactic radiotherapy, to standard immunotherapy can control cancer longer in adults with high-risk advanced hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming, Immunotherapy
- Trial name
- HCC-PULSAR (NCT07884877)
- Testing
- PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Samsung Medical Center
HCC - Hepatocellular Carcinoma, Cirrhosis
Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma
This is a single-centre, prospective cohort study. Consecutive patients with compensated liver disease and hepatocellular carcinoma (HCC) for curative-intent treatment will be invited to this study.
- Trial name
- NCT07036874
- Testing
- transient elastography and oesophagogastroduodenoscopy
- Where
- Hong Kong
- Volunteers
- 159 people
- Sponsor
- Chinese University of Hong Kong
Hepatocellular Carcinoma (HCC)
SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
SBRT combined with dual PD-1/CTLA-4 blockade (iparomlimab and tuvonralimab, QL1706) and bevacizumab may provide complementary local and systemic antitumor activity in hepatocellular carcinoma (HCC).
- Trial name
- NCT07882056
- Testing
- Stereotactic Body Radiotherapy, Bevacizumab, Iparomlimab and Tuvonralimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma (HCC)
Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma
The goal of this clinical trial is to evaluate the combination of zanzalintinib (XL092) and tegavivint in advanced hepatocellular carcinoma (HCC) and Wnt pathway mutations who have progressed after at least one prior line of…
- Trial name
- NCT07878689
- Testing
- Zanzalintinib, Tegavivint
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Texas Southwestern Medical Center
OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC)
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at…
- Conditions
- OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
- Trial name
- NCT06841172
- Testing
- radiotherapy, Systemic therapy (Continuation of current first-line systemic therapy), Systemic therapy (Early switch to second-line systemic therapy)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma (HCC), Liver Cancer, Adult
Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated…
- Trial name
- NCT07682454
- Testing
- Parenchymal Blood Volume (PBV) Imaging, Nitroglycerin, Medical Record Review
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Advanced Hepatocellular Carcinoma (HCC)
Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
This is a prospective, single-center, single-arm Phase II pilot study designed to evaluate the efficacy and safety of FMT in combination with QL1706 and Bevacizumab as first-line treatment for advanced Hepatocellular carcinoma.
- Trial name
- NCT07847671
- Testing
- FMT combined with QL1706 plus Bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Hepatocellular Carcinoma (HCC)
STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma
STRATHEP develops and validates a multimodal AI model to predict treatment response in advanced hepatocellular carcinoma. By integrating digital pathology and MRI radiomics, the project identifies patients likely to benefit from…
- Trial name
- STRATHEP (NCT07863258)
- Where
- 5 sites in Belgium
- Volunteers
- 280 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic
Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic, Hepatocellular Carcinoma Non-Resectable
- Trial name
- NCT07861425
- Testing
- ACE723
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- Acepodia Biotech, Inc.
HCC - Hepatocellular Carcinoma, Watch & Wait
Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
The "Surgery versus Maintenance after Conversion-therapy-achieved Complete/Partial Response in Hepatocellular Carcinoma (SWITCH)" study is a multicenter, open-label, prospective non-randomized cohort study with the protocol…
- Conditions
- HCC - Hepatocellular Carcinoma, Watch & Wait, Surgery
- Trial name
- SWITCH (NCT07410715)
- Testing
- Surgical Resection, Maintenance Therapy Group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- West China Hospital
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma(HCC)
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy.
- Trial name
- ICT-HCC (NCT06893887)
- Testing
- FOLFOX4, Adebrelimab, Apatinib
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Nanjing Tianyinshan Hospital
HCC - Hepatocellular Carcinoma, Durvalumab
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab, Proton Radiotherapy
- Trial name
- Proton-STRIDE (NCT06999694)
- Testing
- Proton radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
HCC - Hepatocellular Carcinoma, Tremelimumab
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, Radiotherapy
- Trial name
- Photon-STRIDE (NCT06999707)
- Testing
- Photon radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital